Oncotarget

Research Papers:

Sphingosine-1-phosphate promotes ovarian cancer cell proliferation by disrupting Hippo signaling

Qianlan Fan, Yuan Cheng, Hsun-Ming Chang, Masashi Deguchi, Aaron J. Hsueh and Peter C.K. Leung _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:27166-27176. https://doi.org/10.18632/oncotarget.15677

Metrics: PDF 1016 views  |   HTML 1516 views  |   ?  


Abstract

Qianlan Fan1,*, Yuan Cheng2,*, Hsun-Ming Chang1, Masashi Deguchi2, Aaron J. Hsueh2, Peter C.K. Leung1

1Department of Obstetrics and Gynaecology, British Columbia Children’s Hospital Research Institute, University of British Columbia, Vancouver, British Columbia, V5Z 4H4, Canada

2Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, CA 94305-5317, USA

*These authors have contributed equally to this work

Correspondence to:

Peter C.K. Leung, email: peter.leung@ubc.ca

Keywords: Hippo, YAP, CCN1, CCN2, ovarian cancer

Received: April 28, 2016     Accepted: February 06, 2017     Published: February 24, 2017

ABSTRACT

Epithelial ovarian carcinomas account for more than 90% of human ovarian cancers and have become the primary cause of death for gynecological malignancies. Unlimited cell proliferation and resistance to cell apoptosis contribute to the development of ovarian cancers. However, the underlying mechanisms involved in these processes in epithelial ovarian carcinomas are yet poorly understood. In the present study, we examined the Hippo signaling gene expression and investigated the effects of Sphingosine 1-phosphate (S1P) on cell proliferation and the underlying mechanisms in human ovarian cancer cell lines, OVCAR3 and SKOV3. Our results demonstrate that S1P disrupts Hippo signaling by reducing YAP phosphorylation and increasing the expression of CCN1 and CCN2 in both ovarian cancer cells. Furthermore, the increase in CCN1/CCN2 expression contributes to the S1P-induced increase in cancer cell proliferation.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 15677